Ablynx Competitors and Similar CompaniesClear all
Ablynx's competitors and similar companies include ImmunoGen, Innate Pharma and Genfit.
 Ablynx Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments. |  ImmunoGen ImmunoGen is a biotechnology company focused on the development of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. |  Innate Pharma Innate Pharma is a clinical-stage biotechnology company with a focus on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. |  Genfit GENFIT is a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions to address high unmet patient needs. | |
Founding Date | Founding Date 2001 | Founding Date 1981 | Founding Date 1999 | Founding Date 1999 |
Type | Type Subsidiary | Type Public | Type Public | Type Public |
Tags | ||||
Locations | Locations Gent, BE HQ | Locations Waltham, US HQ | Locations Marseille, FR HQ Rockville, US | Locations Loos, FR HQ Cambridge, US |
Employees | Employees 1401% decrease | Employees 277161% increase | Employees 168 | Employees 1696% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) 8.7 b | Valuation ($) 148.6 m | Valuation ($) 280.8 m |
Financial | ||||
Revenue (est.) | Revenue (est.) €85.2m (FY, 2016) | Revenue (est.) $108.8m (FY, 2022) | Revenue (est.) €51.9m (FY, 2023) | Revenue (est.) €28.6m (FY, 2023) |
Cost of goods | Cost of goods N/A | Cost of goods $176k (FY, 2022) | Cost of goods €244k (FY, 2023) | Cost of goods €547k (FY, 2023) |
Gross profit | Gross profit N/A | Gross profit $108.6m (FY, 2022) | Gross profit €61.4m (FY, 2023) | Gross profit €38.1m (FY, 2023) |
Net income | Net income (€1.1m) (FY, 2016) | Net income ($222.9m) (FY, 2022) | Net income (€7.6m) (FY, 2023) | Net income (€28.9m) (FY, 2023) |
Operating ⚠ | ||||
Patents (Foreign) | Patents (Foreign) 180 (Q2, 2017) | Patents (Foreign) N/A | Patents (Foreign) N/A | Patents (Foreign) 450 (FY, 2019) |
Patents (US) | Patents (US) 50 (Q2, 2017) | Patents (US) N/A | Patents (US) N/A | Patents (US) 28 (FY, 2019) |
Funding | ||||
Total funding raised | Total funding raised $ 498.8m | Total funding raised $ 56m | Total funding raised $ 94.1m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
ImmunoGen
HQ
Waltham, US
Employees
277
ImmunoGen is a biotechnology company focused on the development of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients.
View companyInnate Pharma
HQ
Marseille, FR
Employees
168
Innate Pharma is a clinical-stage biotechnology company with a focus on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients.
View companyGenfit
HQ
Loos, FR
Employees
169↑ 6% increase
GENFIT is a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions to address high unmet patient needs.
View company